RxDoctor Payments DataLook up a doctor →

Alexander Greiner, MD

Allergy & Immunology · San Diego, CANPI 1609801299

Payments from drug & device makers

$4,760,342in general payments, 2019–2025

Across 870 payments — averaging $5471.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1.9M
  • Aimmune Therapeutics, Inc.$599K
  • Teva Pharmaceuticals USA, Inc.$588K
  • Amphastar Pharmaceuticals, Inc.$391K
  • Cipla USA Inc.$311K
  • Hikma Pharmaceuticals USA$231K
  • plus $733K from 33 others

What the payments were for

  • Consulting fees$2,9106%
  • Speaking & faculty fees$40,47379%
  • Travel & lodging$2,5345%
  • Food & beverage$5,44011%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,760,342 in reported general payments places this provider in the 95th percentile of 426 allergy & immunology providers in California.

See all allergy & immunology providers in California

Medicare billing

Part B allowed, 2024
$10,013
Medicare patients
42
Services billed
482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab24$113,042
Dupixent SyringeDupilumab12$45,445
XolairOmalizumab13$34,965
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$22,513
Advair HfaFluticasone Propion/Salmeterol11$7,665
Breo ElliptaFluticasone/Vilanterol14$7,046
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$3,128
Arnuity ElliptaFluticasone Furoate14$3,117
Theophylline ErTheophylline Anhydrous13$822
Ipratropium Bromide19$785
Albuterol Sulfate HfaAlbuterol Sulfate23$689
Fluticasone Propionate23$387
Montelukast Sodium18$208
Famotidine14$208
Prednisone11$84

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$89,793$32,67651 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 426 allergy & immunology providers in California.

Other allergy & immunology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →